Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz plus P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).

Author
Hitier, Simon
Basaran, Mert
Matus, Geoffrey
Heidenreich, Axel
Bahl, Amit
Malik, Zafar
di Lorenzo, Giuseppe
Bracarda, Sergio
Ardavanis, Alexandros
Parente, Phillip
de Schultz, Wito
Saad, Fred
van Oort, Inge
Gerritsen, Winald R.
Aparicio, Luis M. Anton
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/50027
https://doi.org/10.1200/jco.2014.32.4_suppl.242
Collections